
    
      PRIMARY OBJECTIVES:

      I. To evaluate the efficacy of study drug in improving chronic lymphedema while further
      elucidating the role of inflammatory and lymphangiogenic processes in the pathogenesis of
      this disease.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive study drug orally (PO) thrice daily (TID) for up to 1 year in the
      absence of disease progression or unacceptable toxicity.

      ARM II: Patients receive placebo PO TID for up to 1 year in the absence of disease
      progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up for 5 years.
    
  